1887
Research Open Access
Like 0

Abstract

Background

Evidence of an oseltamivir treatment effect on influenza A(H3N2) virus infections in hospitalised patients is incomplete.

Aims

This cohort study aimed to evaluate risk factors for death among PCR-confirmed hospitalised cases of seasonal influenza A(H3N2) of all ages and the impact of oseltamivir.

Methods

Participants included all 332 PCR-confirmed influenza A(H3N2) cases diagnosed between 30 August 2016 and 17 March 2017 in an English university teaching Hospital. Oseltamivir treatment effect on odds of inpatient death was assessed by backward stepwise multivariable logistic regression analysis.

Results

The odds of death were reduced by two thirds (odds ratio (OR): 0.32; 95% confidence interval (CI): 0.11–0.93), in inpatients treated with a standard course of oseltamivir 75 mg two times daily for 5 days – compared with those untreated with oseltamivir, after adjustment for age, sex, current excess alcohol intake, receipt of 2016/17 seasonal influenza vaccine, serum haemoglobin and hospital vs community attribution of acquisition of influenza.

Conclusions

Oseltamivir treatment given according to National Institutes of Clinical Excellence (NICE); United States Centres for Disease Control and Prevention (CDC); Infectious Diseases Society of America (IDSA) and World Health Organization (WHO) guidelines was shown to be effective in reducing the odds of mortality in inpatients with PCR-confirmed seasonal influenza A(H3N2) after adjustment in a busy routine English hospital setting. Our results highlight the importance of hospitals complying with relevant guidelines for prompt seasonal influenza PCR testing and ensuring standard oseltamivir treatment to all PCR-confirmed cases of seasonal influenza.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.44.1900087
2019-10-30
2019-11-13
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.44.1900087
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/44/eurosurv-24-44-1.html?itemId=/content/10.2807/1560-7917.ES.2019.24.44.1900087&mimeType=html&fmt=ahah

References

  1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-300.  https://doi.org/10.1016/S0140-6736(17)33293-2  PMID: 29248255 
  2. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, Cozza V, et al. WHO Working Group on Influenza Burden of Disease. Advances in measuring influenza burden of disease. Influenza Other Respir Viruses. 2018;12(1):3-9.  https://doi.org/10.1111/irv.12533  PMID: 29460425 
  3. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-40.  https://doi.org/10.1001/jama.292.11.1333  PMID: 15367555 
  4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-86.  https://doi.org/10.1001/jama.289.2.179  PMID: 12517228 
  5. Chaves SS, Aragon D, Bennett N, Cooper T, D’Mello T, Farley M, et al. Patients hospitalized with laboratory-confirmed influenza during the 2010-2011 influenza season: exploring disease severity by virus type and subtype. J Infect Dis. 2013;208(8):1305-14.  https://doi.org/10.1093/infdis/jit316  PMID: 23863950 
  6. van Asten L, van den Wijngaard C, van Pelt W, van de Kassteele J, Meijer A, van der Hoek W, et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis. 2012;206(5):628-39.  https://doi.org/10.1093/infdis/jis415  PMID: 22723641 
  7. Wu P, Goldstein E, Ho LM, Yang L, Nishiura H, Wu JT, et al. Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis. 2012;206(12):1862-71.  https://doi.org/10.1093/infdis/jis628  PMID: 23045622 
  8. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568-75.  https://doi.org/10.1086/523584  PMID: 18190317 
  9. Frieden TR. Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. N Engl J Med. 2017;377(5):465-75.  https://doi.org/10.1056/NEJMra1614394  PMID: 28767357 
  10. Uyeki TM. Influenza. Ann Intern Med. 2017;167(5):ITC33-48.  https://doi.org/10.7326/AITC201709050  PMID: 28869984 
  11. Penttinen PM, Friede MH. Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge? Euro Surveill. 2016;21(38):30350.  https://doi.org/10.2807/1560-7917.ES.2016.21.38.30350  PMID: 27684999 
  12. Bresee J, Fitzner J, Campbell H, Cohen C, Cozza V, Jara J, et al. WHO Working Group on the Burden of Influenza Disease. Progress and Remaining Gaps in Estimating the Global Disease Burden of Influenza. Emerg Infect Dis. 2018;24(7):1173-7.  https://doi.org/10.3201/eid2407.171270  PMID: 29912681 
  13. Public Health England (PHE). Surveillance of influenza and other respiratory viruses in the UK 2016 to 2017. London: PHE; 2017.
  14. Pebody RG, Warburton F, Andrews N, Sinnathamby M, Yonova I, Reynolds A, et al. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. Euro Surveill. 2018;23(39).  https://doi.org/10.2807/1560-7917.ES.2018.23.39.1800092  PMID: 30280688 
  15. Kissling E, Rondy MI-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):30464.  https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464  PMID: 28230524 
  16. World Health Organisation (WHO). WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010. Geneva: WHO; 2009.
  17. Centers for Disease Control and Prevention (CDC). Seasonal Influenza Vaccine Effectiveness, 2004-2018. Atlanta: CDC; 2018. Available from: https://wwwcdcgov/flu/professionals/vaccination/effectiveness-studieshtm.
  18. National Institute for Health and Care Excellence (NICE) NIoCE. NICE guidance amantadine, oseltamivir and zanamivir ta 168 2009’; 2009. [Accessed 30 Jul 2019]. Available from: https://www.nice.org.uk/Guidance/ta168
  19. National Institute for Health and Care Excellence (NICE). NICE Influenza Pathway; 2018. [Accessed 30 July 2019]. Available from: https://pathways.nice.org.uk/pathways/influenza#content=view-index
  20. Center for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians: Treatment Considerations for Patients Hospitalized with Suspected or Confirmed Influenza 2019. [Accessed 30 July 2019]. Available from: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Table1
  21. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TMCenters for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24. PMID: 21248682 
  22. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019;68(6):895-902.  https://doi.org/10.1093/cid/ciy874  PMID: 30834445 
  23. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53(3):277-9.  https://doi.org/10.1093/cid/cir400  PMID: 21677258 
  24. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729-37.  https://doi.org/10.1016/S0140-6736(14)62449-1  PMID: 25640810 
  25. European Union (EU). The EU general data protection regulation 2016/679 (GDPR) Article 9 EU GDPR “Processing of special categories of personal data”. [Accessed 30 Jul 2019]. Available from: https://eugdpr.org/
  26. UK Government. The Data protection Act 2018. [Accessed 30 July 2019]. Available from: https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/
  27. Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect. 2014;69(5):507-15.  https://doi.org/10.1016/j.jinf.2014.07.023  PMID: 25108123 
  28. Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76-86.  https://doi.org/10.1183/09031936.00092214  PMID: 25186260 
  29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.  https://doi.org/10.1016/0021-9681(87)90171-8  PMID: 3558716 
  30. British National Formulary (BNF). Free online access to the UK BNF (British National Formulary) content published by NICE. Oseltamivir Directions for Administration. [Accessed 29 Oct 2019]. Available from: https://bnf.nice.org.uk/drug/oseltamivir.html#directionsForAdministration
  31. Rothman KJ, Greenland S. Modern Epidemiology. 2nd. ed. Philadelphia: Lippincott, Williams and Wilkins; 1998. Chapter 4 Measures of effect and association 47 -66; Chapter 5 Types of epidemiological study 67-78; Chapter 20 Introduction to Regression Models 359-358; Chapter 21 Introduction to Regression Modeling. p 401-343.
  32. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, et al. Influenza Clinical Information Network (FLU-CIN). Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax. 2012;67(8):709-17.  https://doi.org/10.1136/thoraxjnl-2011-200266  PMID: 22407890 
  33. Zhang Z, Pereira SL, Luo M, Matheson EM. Evaluation of Blood Biomarkers Associated with Risk of Malnutrition in Older Adults: A Systematic Review and Meta-Analysis. Nutrients. 2017;9(8):E829.  https://doi.org/10.3390/nu9080829  PMID: 28771192 
  34. Kmietowicz Z. Study claiming Tamiflu saved lives was based on "flawed" analysis. BMJ. 2014;348(mar18 3):g2228.  https://doi.org/10.1136/bmj.g2228  PMID: 24646608 
  35. Kmietowicz Z. Critics attack chief medical officer’s advice to use antivirals for flu. BMJ. 2014;348(feb12 4):g1496.  https://doi.org/10.1136/bmj.g1496  PMID: 24526786 
  36. Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990-3007.  https://doi.org/10.1093/jac/dkx271  PMID: 28961794 
  37. Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1-242.  https://doi.org/10.3310/hta20420  PMID: 27246259 
  38. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(apr09 2):g2545.  https://doi.org/10.1136/bmj.g2545  PMID: 24811411 
  39. prevention Cfdca. “Have You Heard?” CDC recommendations for influenza antiviral medications remain unchanged. [Accessed 30 Jul 2019]. Available from: http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html
  40. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TMCenters for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24. PMID: 21248682 
  41. Beard KR, Brendish NJ, Clark TW. Treatment of influenza with neuraminidase inhibitors. Curr Opin Infect Dis. 2018;31(6):514-9.  https://doi.org/10.1097/QCO.0000000000000496  PMID: 30320639 
  42. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, et al. PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404.  https://doi.org/10.1016/S2213-2600(14)70041-4  PMID: 24815805 
  43. Jones M, Del Mar C, Hama R. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014;2(7):e9-10.  https://doi.org/10.1016/S2213-2600(14)70126-2  PMID: 24948431 
  44. Wolkewitz M, Schumacher M. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014;2(7):e8-9.  https://doi.org/10.1016/S2213-2600(14)70115-8  PMID: 24948434 
  45. Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512-24.  https://doi.org/10.7326/0003-4819-156-7-201204030-00411  PMID: 22371849 
  46. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492-500.  https://doi.org/10.1086/600383  PMID: 19591575 
  47. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol. 2007;28(9):1071-6.  https://doi.org/10.1086/520101  PMID: 17932829 
  48. Wolkewitz M, Schumacher M. Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data. PLoS One. 2016;11(9):e0160430.  https://doi.org/10.1371/journal.pone.0160430  PMID: 27583403 
  49. Wolkewitz M, Schumacher M. Survival biases lead to flawed conclusions in observational treatment studies of influenza patients. J Clin Epidemiol. 2017;84:121-9.  https://doi.org/10.1016/j.jclinepi.2017.01.008  PMID: 28188897 
  50. Lytras T, Mouratidou E, Andreopoulou A, Bonovas S, Tsiodras S. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study. Clin Infect Dis. 2019.  https://doi.org/10.1093/cid/ciz101  PMID: 30753349 
/content/10.2807/1560-7917.ES.2019.24.44.1900087
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error